Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
Location: United States
Employees: 11-50
Total raised: $362.5M
Founded date: 2018
Investors 5
| Date | Name | Website |
| 20.02.2021 | Logos Capi... | logoscapit... |
| - | Access Bio... | accessbio-... |
| - | RA Capital... | racap.com |
| - | Atlas Vent... | atlasventu... |
| - | Canaan Par... | canaan.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 13.06.2022 | - | $172.5M | - |
| 11.02.2021 | Series B | $130M | - |
| 22.05.2020 | Series A | $60M | - |
Mentions in press and media 19
| Date | Title | Description |
| 07.03.2026 | Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio | Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 bill... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 08.12.2024 | Atlas Venture: $450 Million Fund XIV Closed To Invest In Biotech Innovation | Atlas Venture—a leading early-stage venture capital firm investing in biotech innovation—announced closing its fourteenth fund, raising $450 million in an oversubscribed fundraise. Through Fund XIV, Atlas Venture will continue collaborating... |
| 29.04.2024 | Pediatric Brain Tumor Foundation celebrates FDA approval of Day One Biopharmaceuticals’ OJEMDA™, new treatment for common pediatric brain tumor type | Early research funding from the PLGA Foundation contributed to development of OJEMDA (tovorafenib), the first-of-its-kind treatment for pediatric low-grade glioma (pLGG), the most commonly diagnosed pediatric brain tumor BOSTON, April 29, 2... |
| 26.04.2024 | FDA Roundup: April 26, 2024 | SILVER SPRING, Md., April 26, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA published the FDA Voices: "A Milestone in Facilitating t... |
| 30.10.2023 | Your Monday morning biotech news roundup | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey there. Today, we discuss why Sanofi’s stock crashed, what Sarepta’s new Duchenne data will mean for the company ... |
| 01.05.2023 | Day One Reports First Quarter 2023 Financial Results and Corporate Progress | /EIN News/ -- FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team strengthened with executive appointments in clinical development and commercial... |
| 06.03.2023 | Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress | /EIN News/ -- First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma (pLGG) Reported topline data in January 2023 fro... |
| 13.06.2022 | In early trial, drug shrinks tumors in majority of children with most common form of brain cancer | Day One Biopharmaceuticals reported Sunday that an experimental molecule shrank tumors by at least 50% in a majority of children with the most common form of childhood brain cancer, offering an early but rare glimmer of progress in a diseas... |
| 01.09.2021 | Dayone Capital Closes Fund I, at USD630 M | Dayone Capital Logo Dayone Capital, a Shenzen, China-based private equity firm, closed Dayone Capital Fund I L.P. its first USD-denominated fund, at USD630m. As a debut fund, Dayone Fund I was backed by a group of top global institutional i... |
Show more